美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎的临床效果及对其肺功能的影响分析

Clinical effect of mezlocillin combined with azithromycin in the treatment of Streptococcus pneumoniae pneumonia in children and its influence on their lung function

目的分析美洛西林联合阿奇霉素应用在小儿肺炎链球菌肺炎中的治疗效果以及对其肺功能的影响。方法选择小儿肺炎链球菌肺炎患儿90例,依据随机数字表法分成对照组和研究组,每组45例。对照组采取美洛西林进行治疗,研究组在对照组治疗基础上联合阿奇霉素治疗。对比两组疗效、肺功能、炎症因子、不良反应发生情况。结果治疗后,研究组的总有效率(95.56%)优于对照组(80.00%),差异有统计学意义(P<0.05)。治疗后,研究组的用力肺活量(FVC)(2.68±0.24)L、第1秒用力呼气容积占预计值的百分比(FEV1%)(77.53±4.89)%、第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)(75.53±3.65)%与对照组的(2.57±0.21)L、(70.67±4.47)%、(68.79±4.25)%相比更高,差异有统计学意义(P<0.05)。治疗前,两组白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)对比差异无统计学意义(P>0.05);治疗后,研究组IL-6(45.65±10.12)pg/ml、CRP(37.73±11.23)mg/L、TNF-α(24.34±5.27)ng/L低于对照组的(58.93±13.31)pg/ml、(69.28±16.57)mg/L、(31.75±6.38)ng/L,差异有统计学意义(P<0.05)。治疗后,研究组的不良反应发生率(4.44%)低于对照组(17.78%),差异有统计学意义(P<0.05)。结论美洛西林、阿奇霉素联合应用在小儿肺炎链球菌肺炎中的治疗效果更佳,可帮助患儿改善肺功能,降低炎症及不良反应发生率,临床上值得推广使用。

Objective To analyze the effect of mezlocillin combined with azithromycin in the treatment of Streptococcus pneumoniae pneumonia in children and its influence on their lung function.Methods 90 children with Streptococcus pneumoniae pneumonia were selected and divided into a control group and a study group according to random number table method,with 45 cases in each group.The control group was treated with mezlocillin,and the study group was treated with azithromycin on the basis of the control group.The efficacy,lung function,inflammatory factors and occurrence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the study group(95.56%)was better than that of the control group(80.00%),and the difference was statistically significant(P<0.05).After treatment,the forced vital capacity(FVC)of the study group was(2.68±0.24)L,the forced expiratory volume in one second as a percentage of the predicted value(FEV1%)was(77.53±4.89)%,and the ratio of FEV1 to FVC(FEV1/FVC)was(75.53±3.65)%,which were higher than(2.57±0.21)L,(70.67±4.47)%and(68.79±4.25)%of the control group.The difference was statistically significant(P<0.05).Before treatment,there was no significant difference in interleukin-6(IL-6),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)between the two groups(P>0.05).After treatment,the study group had IL-6 of(45.65±10.12)pg/ml,CRP of(37.73±11.23)mg/L,and TNF-αof(24.34±5.27)ng/L,which were lower than(58.93±13.31)pg/ml,(69.28±16.57)mg/L,and(31.75±6.38)ng/L in the control group,and the difference was statistically significant(P<0.05).After treatment,the incidence of adverse reactions in study group(4.44%)was lower than that in the control group(17.78%),and the difference was statistically significant(P<0.05).Conclusion The combined application of mezlocillin and azithromycin shows excellent effect in the treatment of Streptococcus pneumoniae pneumonia in children,which can help children improve lung function,reduce inflammation and the incidence of adverse reactions,and is worth promoting clinically.